Compare Aon PLC (AON) vs Heron Therapeutics Inc (HRTX) Price & Performance

AON trades at $356.94, up 0.39% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q1 2026 EPS of $6.48 beating expectations and revenue growth from $17.18B in 2025 to projected $17.5B in 2026. Net income margin improved to 22.54% with robust ROE of 46.82%. Recent news highlights dividend declarations and upcoming Q2 earnings.

AON presents a compelling investment case with consistent earnings beats, strong profitability metrics, and analyst consensus target of $399.67 offering 12% upside. Risks include elevated valuation multiples and debt levels, while institutional sentiment remains positive with 50% buy ratings. The stock's technical strength and fundamental growth support continued upward momentum.

HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.

The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.